胃癌根治术后ECF方案对比FU+LV方案辅助放化疗:CALGB 80101研究结果
CALGB 80101(Alliance)是一项III期随机试验,纳入546例胃癌或胃食管结合部腺癌根治术后(IB–IV期M0)患者,比较放疗前后分别使用ECF方案与FU+LV方案辅助放化疗的疗效。多因素HR 0.96,95%CI 0.77–1.20)。结论认为,在放疗前后用ECF多药方案替代FU+LV并未改善生存。
要点
- 事后分析中,治疗效果在所有已检查的患者亚组中似乎相似。
核心结论
- 胃癌或胃食管结合部腺癌根治性切除术后,放疗前后使用ECF多药方案的术后放化疗与标准FU+LV放化疗相比未改善生存。
研究设计与样本
- III期随机试验CALGB 80101(Alliance),2002年4月至2009年5月纳入546例胃癌或胃食管结合部腺癌根治术后(IB–IV期M0)患者,随机分为FU+LV组与ECF组,两组均在放疗前后接受相应化疗。
主要发现
- 事后分析显示治疗效果在所有已检查的患者亚组中似乎相似。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone. CALGB 80101 (Alliance; Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a postoperative chemoradiotherapy regimen that replaced FU plus LV with a potentially more active systemic therapy could further improve overall survival. Patients and Methods Between April 2002 and May 2009, 546 patients who had undergone a curative resection of stage IB through IV (M0) gastric or gastroesophageal junction adenocarcinoma were randomly assigned to receive either postoperative FU plus LV before and after combined FU and radiotherapy (FU plus LV arm) or postoperative epirubicin, cisplatin, and infusional FU (ECF) before and after combined FU and radiotherapy (ECF arm). Results With a median follow-up duration of 6.5 years, 5-year overall survival rates were 44% in the FU plus LV arm and 44% in the ECF arm ( Plogrank = .69; multivariable hazard ratio, 0.98; 95% CI, 0.78 to 1.24 comparing ECF with FU plus LV). Five-year disease-free survival rates were 39% in the FU plus LV arm and 37% in the ECF arm ( Plogrank = .94; multivariable hazard ratio, 0.96; 95% CI, 0.77 to 1.20). In post hoc analyses, the effect of treatment seemed to be similar across all examined patient subgroups. Conclusion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy does not improve survival compared with standard FU and LV before and after radiotherapy.
引用
- Fuchs CS, Niedzwiecki D, Mamon HJ, et al. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017. PMID: 28976791. doi:10.1200/JCO.2017.74.2130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。